Subsidies & Funding

We empower medical innovation

Project Management

We manage your EU Horizon 2020 project

Business Strategy

We support successful commercialisation

Funding database

EU & non EU subsidies

News

Funding opportunities for SMEs this fall

July 27 2016

This fall, there are several opportunities for SMEs to apply for EU funding, both independently and as part of an international consortium.

 


Opportunity

Purpose

Funding per project

Funding rate

Deadline

SME Instrument-02 Phase II 

Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs

€ 0.5 – 2.5 million


70%

13-10-2016
 

SME Instrument-03 Phase II

Dedicated support to biotechnology SMEs closing the gap from lab to market

€ 0.5 – 2.5 million


70%

13-10-2016
SME Instrument-05 Phase II

Supporting innovative SMEs in the healthcare biotechnology sector

€ 1 – 5 million

100%

13-10-2016

SME Instrument-06 Phase II

Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well

€ 0.5 – 2.5 million

70%

13-10-2016

Fast Track to Innovation (FTI)

Projects undertaking innovation form the demonstration stage through to market uptake – relatively mature new technologies that will achieve market entry within 3 years

€ 2 - 3 million

70%

25-10-2016

 

€ 3 million from the Horizon 2020 Fast Track to Innovation (FTI) programme, 25 October deadline

FTI provides bottom-up funding for projects that are close to market (market entry has to be achieved within 3 years after project start). Projects may relate to any field under the specific objective "Leadership in enabling and industrial technologies" and/or to any of the specific objectives under the priority "Societal challenges"(e.g. all the Personalised Heatlh and Care calls).

Specific FTI objectives are to:

  • Reduce time from idea to market;
  • Stimulate the participation of first-time to EU research funding;
  • Increase private sector investment in research and innovation

Applying requires consortia of at least 3 and maximally 5 independent entities from at least 3 different EU countries.

€ 0.5 – 5 million from Horizon 2020 SME Instrument phase 2, 13 October deadline

Phase 2 of the Horizon 2020 SME Instrument sponsors individual SMEs. These calls focus on the support of innovation projects that match each programme’s specific challenges, and that will significantly boost the requesting company’s competitiveness and growth. Activities can include demonstration, testing, prototyping, piloting, scaling-up, miniaturisation, design, and market replication, and should be aimed at preparing a product or service for market introduction; nonetheless, a project may include some research. Funding entails Eur 0.5 – 2.5M per project at 70% funding rate, and for SMEInst05 (see below) 1 – 5M at 100% funding rate.

SME phase 2 calls of interest to the biomedical sector

SMEInst-02: Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs

There are several topics, amongst which: Accelerating the uptake of nanotechnologies, advanced materials or advanced manufacturing and processing technologies by SMEs. The goal is to creatively combine existing research results with other necessary elements, to transfer results across sectors where applicable, to accelerate innovation and eventually create profit or other benefits. Research should have potential in the field of nanotechnologies, advanced materials and advanced manufacturing and processing technologies.

SMEInst-03: Dedicated support to biotechnology SMEs closing the gap from lab to market

The goal is to support SMEs in the field of biotechnology and help them overcome the obstacles between early technological development and market introduction. SMEs working in the field of industrial biotechnology and ideas/concepts involving the use of systems and/or synthetic biology are particularly invited to apply for funding.

SMEInst05: Supporting SMEs developing cell technologies for medical applications

This call focuses on Cell technologies in medical applications. Cell technologies include cell manufacturing (culture, multiplication, scale-up and automation), preservation, banking and transport; identification, cell sorting and delivery, imaging, tracking, process and quality control; genetic engineering and gene editing; production of therapeutic biomolecules. The medical applications of cell technologies include diagnostics and biosensors; cell and gene therapy, tissue engineering, bio-artificial organs, haematology, immunotherapy, and vaccine and antibody production; predictive toxicology, synthetic biology, and modelling development and disease processes. The challenge addresses cells from any eukaryotic source though their eventual application must be to human medicine.

SMEInst06: Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well

This call focuses on overcoming the current gaps in exploitation of promising research results in ICT for Health, Well-being and Ageing Well, and to stimulate increased availability and market uptake of relevant ICT products and services. This concerns both interoperable and secure eHealth solutions for consumers and institutional healthcare delivery building on standards and new ICT solutions and innovation ecosystems for ageing well, building on open software platforms, in order to deliver new and more efficient care to European citizens and respond to new market opportunities for SMEs.

For more information please visit our Funding Database or contact an advisor.

Share this